OPEN END TURBO OPTIONSSCHEIN SHORT - BRISTOL-MYERS SQUIBB | Real-time BOERSE MUENCHEN 15:26:07 17/06/2024 BST | ||
| 2.877 EUR | +1.91% |
|
| Current month | -0.11% | ||
| 1 month | +12.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 2.877 | +1.91% |
| 14/06/24 | 2.823 | +0.50% |
| 13/06/24 | 2.809 | +5.05% |
| 12/06/24 | 2.674 | -0.93% |
| 11/06/24 | 2.699 | -1.10% |
Real-time BOERSE MUENCHEN
Last update June 17, 2024 at 03:26 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Goldman Sachs |
| WKN | GQ4QW5 |
| ISIN | DE000GQ4QW57 |
| Date issued | 11/09/2023 |
| Strike | 71.72 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.926 € |
|---|---|
| Lowest since issue | 1.14 € |
| Spread | 0.01 € |
| Spread % | 0.35% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat